Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So tell us, were your prior investments in Amarantus with Gerald at the helm based on lies or inaccurate figures in filings (you know, the stuff that REALLY matters), or were they based on predictions that failed to materialize? Did Gerald reveal things to you in your private communications that you took to be facts given in confidence (and in violation of law) that were later revealed to be false?
What made you invest so much with Gerald in Amarantus when there were little or no revenues ever reported in the filings, only acquisitions and testing of potential assets that were speculative until proven effective? Spell it out for us, please.
Again, this was a penny stock up until the time of their reverse split.
So, you are saying you DID listen to the entire interview where GC clearly discussed the acquisition of Provista Labs, but still posted the photo of the guy heading up Provista Labs from an earlier video as part of your rant?
SEC filings of financials and contracts/agreements provide the facts. Forward-looking statements provide goals and predictions that may not pan out. Some here clearly confuse facts with predictions. If someone sets and discusses a goal or predicts an outcome and it doesn't work out, that's not a lie. Investors should understand the difference and the risk associated with investing based on predictions vs facts. Unfortunately, some don't and invest far too much based on predictions, and them blame the CEO entirely when they lose money and fail to become wealthy as they hoped they would. Some become so enthusiastic in their investment based on goals and predictions they engage family, friends, and others on message boards encouraging them to invest also. I suppose claiming the CEO lied to them is how they try to save face, instead of accepting the fact they invested entirely based on speculation and predictions of how things would turn out. That's another reason the share price was penny stock range when they invested, since it was priced accordingly in the market based on the risk and lack of actual financials to support a higher share price.
From Investopedia:
https://www.investopedia.com/terms/f/forward-looking.asp
Outstanding Shares Update - 8/20/21
https://www.otcmarkets.com/stock/tomdf/security
The concerns of a non-shareholder are truly touching. Thanks for sharing.
In case you didn't know, the guy in the last photo was over Provista Labs, which Todos acquired, so it is inappropriate to include that in this axe-grinding rant.
Listening to the actual interview instead of posting blindly about it can help to prevent these kinds of obvious errors. The interview was 31 minutes in length. Probably only an actual shareholder would feel the time to view it was worth the effort. But thanks again for pointing out things shareholders already know, yet choose to remain invested.
Todos Medical Presentation at Emerging Growth Conference - 8/18/21
CEO on Newsy Interview
Why do you need a booster shot now?
— Scripps News (@scrippsnews) August 18, 2021
CEO of Todos Medical, @G_Commish explains the science behind booster shots, what's in the COVID-19 vaccine and why people who received the Johnson & Johnson vaccine don't need a second or third shot. pic.twitter.com/tFo8VlmpjU
How about another Come to Jesus chat so we can rally the shareholders. Do you still have Gerald on speed dial? Tell us again how the "whales" are buying shares and beg longs to support the share price while you secretly unload your shares.
You can't make this stuff up!!
BTW, he's not "my guy". I'm a shareholder posting info about the company. Nothing more. I don't come here to post as a non-shareholder who continues to be infatuated with Gerald. I think you sat next to him at a Amarantus shareholders meeting, probably making google eyes at him.
The Dominant Delta Variant and Lambda Variant Lurking in the Shadows
by Gerald Commissiong
Published on August 11, 2021
https://www.linkedin.com/pulse/dominant-delta-variant-lambda-lurking-shadows-gerald-commissiong
The Gerald addiction continues. Sad.
FORM 12b-25 NOTIFICATION OF LATE FILING
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-21-020136/0001493152-21-020136.pdf
Due Monday 16th. No filing deadlines are on a weekend.
Outstanding Shares Update - 9/13/21
https://www.otcmarkets.com/stock/tomdf/security
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™
(I didn't see a previous post or link to this story, so posting it a week later)
New York, NY, and Tel Aviv, ISRAEL, Aug. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has received a notice of allowance from the US Patent & Trademark Office (USPTO) for a trademark for the Company’s proprietary supplement Tollovid™. The Company received a Certificate of Free Sale (CFS) for the 5-day high dose regimen of Tollovid from the US Food & Drug Administration (US FDA) in April 2021.
This USPTO notice of allowance underscores the desire in the marketplace for Tollovid, especially given its high dose, 5-day formulation that helps to support and maintain healthy immune function. Tollovid is a potent botanical, delayed release, bioavailable 3CL protease inhibitor. The Company’s lower dose, delayed release, daily-use formulation Tollovid Daily™ received a CFS from the US FDA in July 2021, including the critical 3CL protease inhibitor claim. Tollovid has high 3CL protease inhibitor activity than Tollovid Daily.
The Company is currently completing marketing plans for the US distribution of Tollovid™ (high dose, 5-day formulation) and Tollovid Daily™ (lower dose, daily use formulation), and has made Tollovid available to the market in the United States via www.MyTollovid.com and via The Alchemist Kitchen (https://www.thealchemistskitchen.com/products/tollovid), its SoHo, NYC based retail distribution partner that specializes in best of breed herbal supplements. The Company is working closely with the Alchemist Kitchen to implement best practices from a customer service perspective as it relates to the compliant use of botanical products to help support proper immune function.
“We are making diligent, regulatory compliant progress in terms of bringing our 3CL protease-related ‘Tollo’-branded technologies to the marketplace,” said Gerald E. Commissiong, President & CEO of Todos Medical. “It is clear that we have carved out a niche in the marketplace for 3CL protease inhibitor products, and that interest in these products is growing rapidly heading into the second half of 2021. We intend to remain fully regulatory compliant, and will seek to add additional data to the claims we ultimately intend to make for our various ‘Tollo’ branded products as we move forward in the second half of 2021 under the current uncertain market conditions. We intend to have both our Tollovid and Tollovid Daily products available on a first come first serve basis for their individual use cases in August 2021. We believe the second half of 2021 will be an extremely vibrant period for the development of 3CL protease inhibitors with significant human exposure data, and we firmly believe there is no other company in the world ahead of Todos Medical in this arena.”
https://investor.todosmedical.com/news-events/press-releases/detail/122/update-todos-medical-receives-trademark-notice-of
CEO on Twitter - 8/2/21
Linked article: https://edition.cnn.com/2021/08/01/health/uk-scientists-covid-variant-beat-vaccines-intl/index.html
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition
Company to ramp up marketing efforts for Provista’s automated capabilities for COVID-19 PCR testing, variant identification, and neutralizing antibody testing
NEW YORK, NY, and TEL AVIV, ISRAEL, Aug. 02, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that it has made the final payment of $1.25 million to complete its $10 million acquisition of Provista Diagnostics, Inc. Provista is a medical diagnostics company based in Alpharetta, Georgia that owns the intellectual property rights to the proprietary breast cancer blood test, Videssa®, and has a diagnostic testing laboratory currently performing COVID-19 PCR testing, primarily for the medical and entertainment industries. Over $50 million in research and development was invested since 2012 to develop the Videssa blood test.
Todos is currently expanding Provista’s marketing team as it works to capitalize on its automated capabilities in COVID-19 PCR testing, variant identification, and neutralizing antibody testing. Todos has completed a $2 million investment in order to upgrade the testing equipment in Provista’s lab. Todos believes its EUA approved cPass neutralizing antibody test will become increasingly important as new variants test the effectiveness of the vaccine. The Company is also continuing with its commercialization plans for its proprietary breast cancer blood test, Videssa®, that provides physicians with actionable information regarding breast cancer risk in women following an inconclusive mammogram result (BI-RADS III or IV), which primarily occurs in women with dense breasts. The test has demonstrated specificity of 98%+ in women over and under the age of 50 and addresses a multi-billion market.
“We are pleased to have now fully completed the acquisition of Provista to add the commercialization opportunity of Videssa as well as to centralize our proprietary diagnostic platforms in spectroscopy, flow cytometry, ELISA, PCR and next-gen sequencing,” said Gerald E. Commissiong, President & CEO of Todos Medical. “We believe the acquisition represents an enormous value creation event that will enable us to achieve a high return on investment. We have already begun to expand our marketing team and complete testing automation for a number of tests we believe will drive growth at our lab, including our cPass neutralizing antibody testing. We believe we are on the leading edge when it comes to automated neutralizing antibody testing because we believe this will be the preeminent way to determine COVID immunity levels and the timing of the booster shots if they become necessary. We expect that Provista will be a substantial driver of revenue in the years to come and look forward to executing on our growth plan to build lasting long-term value for our stockholders.”
For information related to Todos Medical’s COVID-19 testing capabilities, please visit www.todoscovid19.com.
For testing and PPE inquiries, please email sales@todosmedical.com.
https://investor.todosmedical.com/news-events/press-releases/detail/120/todos-medical-makes-final-payment-to-close-provista
CEO on Twitter - 7/30/21
https://twitter.com/i/events/1419889689645912065
Outstanding Shares Update - 7/30/21
https://www.otcmarkets.com/stock/tomdf/security
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir
• Trials will separately enroll non-hospitalized and hospitalized patients
• Clinical trials in India targeted to be adaptive design to enable expansion into pivotal development upon achieving data milestone
New York, NY, and Tel Aviv, ISRAEL, July 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced it has retained the services of Innvocept Global Solutions, an Indian clinical research organization (CRO), to manage 2 adaptive design Phase 2/3 clinical trials the Company is preparing to initiate with its joint venture partner NLC Pharma of its proprietary oral antiviral 3CL protease inhibitor drug candidate Tollovir™ for the treatment of non-hospitalized and hospitalized COVID-19 patients in India. Engaging a CRO is the first step of the regulatory process in India. The Company expects enrollment for both trials to begin in the third quarter of 2021 with initial, trial expansion-enabling data expected in the fourth quarter of 2021 that could make each trial become part of the Company’s global pivotal clinical development program for Tollovir that would begin in the fourth quarter of 2021.
“We are pleased to have completed this critical step of retaining a CRO for Tollovir’s clinical development in India and are very impressed with Innvocept’s deep experience in executing rapidly enrolling FDA quality COVID-19 clinical trials with over 10 completed to date, and successfully working with US-based pharmaceutical companies to execute successful clinical trials in India,” said Gerald E. Commissiong, President & CEO of Todos Medical. “Enrollment is also starting to accelerate in our ongoing 77 patient Phase 2 randomized placebo-controlled trial of Tollovir™ at Shaare Zedek Medical Center in Jerusalem, Israel for the treatment of hospitalized COVID-19 patients. This trial opened enrollment in April 2021 and is also evaluating the use of TolloTest™ as a companion diagnostic for antiviral therapy. TolloTest is the Company’s proprietary 3CL protease biomarker assay that is being developed as a more accurate measure of viral infection, load and infectiousness in COVID-19 patients.”
Mr. Commissiong continued, “As we move forward with the clinical development of Tollovir in Israel, we felt it was critical to have a second program recruiting in a larger, less vaccinated jurisdiction that has the potential for faster recruitment. We believe this dual-track clinical development program in Israel and India will have the benefit of showing Tollovir’s clinical efficacy in hospitalized patients when compared to, or in combination with, different standards of care that are emerging internationally. We are also now heavily engaged in planning Tollovir’s US regulatory strategy and planning for a pre-IND meeting with the US Food & Drug Administration ahead of an IND submission we are hopeful to file in the third quarter of 2021. This submission will set the stage for the opening of a US IND and clinical studies intended to ultimately dovetail our global pivotal clinical development program for Tollovir. The expansion of Tollovir’s clinical development into non-hospitalized patients dramatically opens the potential market opportunity for Tollovir, as it is becoming increasingly clear that vaccinated individuals will become infected with COVID-19 in addition to the unvaccinated and those with waning immunity.”
“We continue to compile non-clinical data that includes the Delta variant and is supportive of a regulatory filing for Tollovir. The initial clinical data gathered during a 32 patient Phase 2 open-label, controlled study conducted in Israel in 2020 at the height of the pandemic showed that Tollovir had statistically significantly improved results on key clinical endpoints including death rate, intubation, and mean time to patient discharge,” said Dr. Dorit Arad, PhD, Chief Scientific Officer of NLC Pharma. “Our internal mechanism of action data indicates that Tollovir possesses both exquisitely strong 3CL protease inhibition activity and anti-cytokine activity, based on distinct molecular mechanisms present in its formulation,” Dr. Arad continued. “This dual mechanism makes Tollovir unique among the emerging class of 3CL protease inhibitors currently in development. Researchers are quickly discovering that the fast-replicating Delta variant has shown an improved ability to out-compete neutralizing antibodies for the ACE2 receptors vs. earlier versions of SARS-CoV-2. The Delta variant heightens the call for a safe and effective oral antiviral therapy that can stop an infected person’s viral load from becoming so significant that it triggers cytokine release syndrome, which can lead to hospitalization, death or Long COVID. We believe Tollovir has addressed both viral replication and cytokine storm activity.”
Todos and NLC are currently finalizing study designs for both of its planned Tollovir Phase 2/3 trials in hospitalized and non-hospitalized patients in India, and Innvocept has already identified the clinical trial sites for these important studies. The Company estimates the direct costs to reach interim data for both trials in India will be collectively be approximately $1 million.
https://investor.todosmedical.com/news-events/press-releases/detail/119/todos-medical-retains-cro-for-covid-19-outpatient-and
8-K out on shareholders meeting. All proposals approved.
https://investor.todosmedical.com/sec-filings/all-sec-filings/content/0001493152-21-017856/0001493152-21-017856.pdf
Sorry, that's 7/26/21